SCHEMBL20488362

SCHEMBL20488362

CC(C)(C)OC(=O)N1CCC2(CC1)OC(C)(C)Cc1ccsc12

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
SCD5 Q86SK9 2/20 0.38
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
AVPR1A P37288 1/20 0.36
TSHR P16473 2/20 0.36
ALOX15 P16050 1/20 0.36
ATM Q13315 1/20 0.36
GPR119 Q8TDV5 3/20 0.36
NR1H2 P55055 1/20 0.35
USP30 Q70CQ3 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ESR2 Q92731 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23223306 0.89 USP2 (0.40) USP2SMN1; SMN2SCD5AVPR1ATSHR
SCHEMBL20487669 0.83 OPRL1 (0.39)
SCHEMBL1807425 0.82 OPRL1 (0.47) USP2SMN1; SMN2AVPR1AGPR119NR1H2
SCHEMBL20486729 0.81 GPR119 (0.37) USP2SMN1; SMN2SCD5ALDH1A1LMNA
SCHEMBL21710554 0.80 USP2 (0.40) USP2SMN1; SMN2SCD5AVPR1AGPR119
SCHEMBL18590703 0.80 USP2 (0.40) USP2SMN1; SMN2SCD5AVPR1AGPR119
SCHEMBL18579748 0.80 USP2 (0.40) USP2SMN1; SMN2SCD5AVPR1AGPR119
SCHEMBL25357154 0.76 USP2 (0.41) USP2SMN1; SMN2SCD5ALDH1A1LMNA
SCHEMBL25356737 0.74 USP2 (0.41) USP2SMN1; SMN2SCD5AVPR1ATSHR
SCHEMBL25360337 0.74 SIGMAR1 (0.48) USP2SMN1; SMN2SCD5AVPR1ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110392688-B Compounds for inhibition of ROR-gamma-T 伊莱利利公司 2021-09-10 CN disclosed
EP-3589637-B1 COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T LILLY CO ELI (US) 2021-04-14 EP disclosed
EP-3589637-B1 COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T LILLY CO ELI (US) 2021-04-14 EP disclosed
US-10603320-B2 Compounds useful for inhibiting ROR-gamma-t ELI LILLY AND COMPANY (US) 2020-03-31 US disclosed
WO-2018160547-A1 COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T ELI LILLY AND COMPANY (US) 2018-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10603320-B2 Compounds useful for inhibiting ROR-gamma-t RORC, RORB, RORA USP2 3559/4885SMN1; SMN2 4643/4885SCD5 2062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.